Published in Lancet on March 01, 2003
Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr (2005) 4.02
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS (2009) 2.91
Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis (2010) 2.86
Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr (2006) 2.15
Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 1.70
Expression of fibroblast growth factor-21 in muscle is associated with lipodystrophy, insulin resistance and lipid disturbances in patients with HIV. PLoS One (2013) 1.50
HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J (2011) 1.34
Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV AIDS (Auckl) (2012) 1.33
The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. AIDS (2007) 1.26
Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi. PLoS One (2012) 1.23
Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr (2006) 1.18
Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr (2009) 1.16
Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. Lung (2007) 1.09
High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study. BMC Pediatr (2012) 1.08
Exercise training reduces central adiposity and improves metabolic indices in HAART-treated HIV-positive subjects in Rwanda: a randomized controlled trial. AIDS Res Hum Retroviruses (2008) 1.07
The effects of exercise training on quality of life in HAART-treated HIV-positive Rwandan subjects with body fat redistribution. Qual Life Res (2008) 1.07
Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr (2005) 1.07
Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc (2013) 1.07
A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis (2011) 1.07
Severity of lipodystrophy is associated with decreased health-related quality of life. AIDS Patient Care STDS (2008) 1.06
HIV-associated lipodystrophy syndrome: A review of clinical aspects. Can J Infect Dis Med Microbiol (2005) 1.02
The effect of different combination therapies on oxidative stress markers in HIV infected patients in Cameroon. AIDS Res Ther (2006) 1.00
LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART. South Afr J HIV Med (2009) 1.00
Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications. Am J Infect Dis (2006) 1.00
Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda. AIDS Res Ther (2007) 0.98
Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study. AIDS Res Ther (2009) 0.98
Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. J Acquir Immune Defic Syndr (2012) 0.94
Does HIV cause cardiovascular disease? PLoS Med (2006) 0.92
HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings. J Int AIDS Soc (2015) 0.91
Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS One (2009) 0.87
HIV-associated adipose redistribution syndrome (HARS): etiology and pathophysiological mechanisms. AIDS Res Ther (2007) 0.86
Alcohol consumption and lipodystrophy in HIV-infected adults with alcohol problems. Alcohol (2009) 0.86
Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs. World J Virol (2015) 0.84
HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact. AIDS Res Ther (2007) 0.84
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. J Antimicrob Chemother (2009) 0.84
New and emerging agents in the management of lipodystrophy in HIV-infected patients. HIV AIDS (Auckl) (2010) 0.83
MRI signal changes of the bone marrow in HIV-infected patients with lipodystrophy: correlation with clinical parameters. Skeletal Radiol (2011) 0.82
Lipodystrophy among patients with HIV infection on antiretroviral therapy: a systematic review protocol. BMJ Open (2014) 0.82
Lipodystrophy in HIV patients: its challenges and management approaches. HIV AIDS (Auckl) (2011) 0.81
The development of simple anthropometric measures to diagnose antiretroviral therapy-associated lipodystrophy in resource limited settings. AIDS Res Ther (2014) 0.81
Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin Exp Immunol (2004) 0.80
Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapy. Clin Exp Immunol (2013) 0.80
Changes in blood pressure, glucose levels, insulin secretion and anthropometry after long term exposure to antiretroviral therapy in South African women. AIDS Res Ther (2015) 0.79
Vitamin D insufficiency and subclinical atherosclerosis in non-diabetic males living with HIV. J Int AIDS Soc (2014) 0.79
Is arterial stiffness in HIV-infected individuals associated with HIV-related factors? Braz J Med Biol Res (2012) 0.79
Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls. Immun Ageing (2015) 0.78
High Prevalence of Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on Antiretroviral Therapy. Pediatr Infect Dis J (2016) 0.78
Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance. BMC Infect Dis (2012) 0.78
Proposed ratios and cutoffs for the assessment of lipodystrophy in HIV-seropositive individuals. Eur J Clin Nutr (2014) 0.78
HIV-associated lipodystrophy: a review from a Brazilian perspective. Ther Clin Risk Manag (2014) 0.78
A Systematic Review of the Effects of Exercise Interventions on Body Composition in HIV+ Adults. Open AIDS J (2015) 0.78
Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria. AIDS Res Treat (2015) 0.77
Longitudinal lactate levels from routine point-of-care monitoring in adult Malawian antiretroviral therapy patients: associations with stavudine toxicities. Trans R Soc Trop Med Hyg (2013) 0.77
Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disorders. AIDS Res Ther (2015) 0.77
Biceps skin-fold thickness may detect and predict early lipoatrophy in HIV-infected children. Pediatr Infect Dis J (2013) 0.77
Assessment of ultrasound for use in detecting lipoatrophy in HIV-infected patients taking combination antiretroviral therapy. AIDS Patient Care STDS (2009) 0.76
Self-reported body fat change in HIV-infected men is a marker of decline in physical health-related quality of life with aging, independent of co-morbidity. PLoS One (2014) 0.76
Cutis Verticis Gyrata in Men Affected by HIV-Related Lipodystrophy. Dermatol Res Pract (2013) 0.75
Hypermetabolic subcutaneous fat in patients on highly active anti-retroviral therapy treatment: Subtle finding with implications. Indian J Nucl Med (2012) 0.75
People living with HIV on ART have accurate perception of lipodystrophy signs: a cross-sectional study. BMC Res Notes (2017) 0.75
HIV-Associated Facial Lipodystrophy: Experience of a Tertiary Referral Center With Fat and Dermis-Fat Compound Graft Transfer. Eplasty (2016) 0.75
Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One (2011) 0.75
A pilot study of brisk walking in sedentary combination antiretroviral treatement (cART)- treated patients: benefit on soluble and cell inflammatory markers. BMC Infect Dis (2017) 0.75
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 8.88
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet (1998) 7.53
Apolipoproteins and ischaemic heart disease: implications for screening. Lancet (1994) 6.62
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med (2008) 3.68
Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS (1999) 3.67
Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med (2001) 3.55
Insertional mutagenesis of genes required for seed development in Arabidopsis thaliana. Genetics (2001) 3.49
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Use of personal medical records for research purposes. BMJ (1994) 3.29
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS (2002) 2.90
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet (1999) 2.80
Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol (2008) 2.74
A primary genetic linkage map for human chromosome 12. Genomics (1987) 2.72
How effective is nicotine replacement therapy in helping people to stop smoking? BMJ (1994) 2.68
The prediction of criminal and violent recidivism among mentally disordered offenders: a meta-analysis. Psychol Bull (1998) 2.60
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med (2000) 2.49
Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet (1992) 2.40
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med (2006) 2.38
Pulmonary cryptococcosis in patients without HIV infection. Chest (1999) 2.31
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis (2004) 2.26
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 2.23
Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis (2001) 2.19
AIDS across Europe, 1994-98: the EuroSIDA study. Lancet (2000) 2.13
An appraisal of the efficacy and cost effectiveness of antenatal screening for hepatitis B. J Med Screen (1997) 2.12
Update on Pneumocystis carinii f. sp. hominis typing based on nucleotide sequence variations in internal transcribed spacer regions of rRNA genes. J Clin Microbiol (1998) 2.11
Vaccinia virus utilizes microtubules for movement to the cell surface. J Cell Biol (2001) 2.10
Sex differences in nevirapine rash. Clin Infect Dis (2000) 2.09
Cardio- and cerebrovascular events in HIV-infected persons. AIDS (2004) 1.98
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol (1997) 1.97
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet (1999) 1.95
Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. J Clin Microbiol (2000) 1.95
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis (2013) 1.91
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
The role of initial AIDS-defining illness in survival following AIDS. AIDS (1995) 1.82
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis (1993) 1.77
Vectors with restriction site banks. IV. pJRD184, a 3793-bp plasmid vector with 49 unique restriction sites. Gene (1985) 1.74
3D time-resolved MR angiography (MRA) of the carotid arteries with time-resolved imaging with stochastic trajectories: comparison with 3D contrast-enhanced Bolus-Chase MRA and 3D time-of-flight MRA. AJNR Am J Neuroradiol (2008) 1.74
Semiconductor quantum dots and quantum dot arrays and applications of multiple exciton generation to third-generation photovoltaic solar cells. Chem Rev (2010) 1.72
Loss to follow-up in an international, multicentre observational study. HIV Med (2008) 1.70
Screening, ethics, and the law. BMJ (1992) 1.67
Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol (1994) 1.67
Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol (2001) 1.61
Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol (1992) 1.61
Measuring children's participation in recreation and leisure activities: construct validation of the CAPE and PAC. Child Care Health Dev (2007) 1.61
Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr (1999) 1.61
Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis (1998) 1.60
Viral proteins expressed on the surface of murine leukemia cells. J Virol (1977) 1.60
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med (1995) 1.59
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia (2008) 1.51
Iridoschisis and keratoconus. Cornea (1994) 1.50
The case for indicator condition-guided HIV screening. HIV Med (2013) 1.48
Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment. Radiother Oncol (1997) 1.47
Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.47
Arabidopsis genes essential for seedling viability: isolation of insertional mutants and molecular cloning. Genetics (2001) 1.46
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Magnetic repulsion of linear accelerator contaminates. Med Phys (1996) 1.41
Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J Infect Dis (1998) 1.41
Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer (2011) 1.41
Dynamic contrast-enhanced T2*-weighted MR imaging of gliomatosis cerebri. AJNR Am J Neuroradiol (2002) 1.40
Fusariotoxicosis from barley in British Columbia. II. Analysis and toxicity of syspected barley. Can J Comp Med (1976) 1.40
Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. J Virol (2004) 1.39
Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett (1994) 1.38
If it's the virus, why aren't we measuring it? Med J Aust (1995) 1.38
Gastric ulceration and suspected vitamin A toxicosis in grower pigs fed fish silage. Can Vet J (1998) 1.38
Prophylaxis and treatment of opportunistic infection in patients on HAART. AIDS Read (2003) 1.38
Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. AIDS (1993) 1.36
A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr (1999) 1.35
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses (2005) 1.34
Identification of Pneumocystis carinii chromosomes and mapping of five genes. Infect Immun (1990) 1.34
HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med (2003) 1.34
Appraisal of anti-smoking advertising by youth at risk for regular smoking: a comparative study in the United States, Australia, and Britain. Tob Control (2003) 1.32
Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS (1996) 1.32
Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis (2004) 1.31
Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J Clin Microbiol (1998) 1.31
Health-related quality of life in childhood epilepsy: the results of children's participation in identifying the components. Dev Med Child Neurol (1999) 1.31
Accuracy of the Alberta Stroke Program Early CT Score during the first 3 hours of middle cerebral artery stroke: comparison of noncontrast CT, CT angiography source images, and CT perfusion. AJNR Am J Neuroradiol (2008) 1.30
Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med (1999) 1.30